BV100 plus Polymyxin B — Competitive Intelligence Brief

BV100 plus Polymyxin B (BV100 plus Polymyxin B) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibiotic. Area: Infectious Disease.

phase 2 Antibiotic Bacterial cell membrane Infectious Disease Small molecule

Target snapshot

BV100 plus Polymyxin B (BV100 plus Polymyxin B) — BioVersys AG. BV100 targets the bacterial cell membrane, disrupting its integrity and leading to cell death, in combination with Polymyxin B, an antibiotic that targets the bacterial cell wall.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
BV100 plus Polymyxin B TARGET	BV100 plus Polymyxin B	BioVersys AG	phase 2	Antibiotic	Bacterial cell membrane
Silvadene	Silver Sulfadiazine	Pfizer	marketed	sulfonamide antimicrobial	bacterial cell membrane and cell wall	1973-01-01
CHG antiseptic body cleanser	CHG antiseptic body cleanser	Baycrest	marketed	Antimicrobial antiseptic	Bacterial cell membrane
Neutrogena Rapid Clear®	Neutrogena Rapid Clear®	GlaxoSmithKline	marketed	Topical antimicrobial/keratolytic agent	Cutibacterium acnes (bacterial cell membranes and proteins)
Intranasal Mupirocin and Topical Chlorhexidine	Intranasal Mupirocin and Topical Chlorhexidine	University of Maryland, Baltimore	marketed	Topical antibiotic combination	Bacterial isoleucyl-tRNA synthetase (mupirocin); bacterial cell membrane and proteins (chlorhexidine)
Colistin/Polymyxin B + Meropenem	Colistin/Polymyxin B + Meropenem	National University of Singapore	marketed	Antibiotic combination (polymyxin + carbapenem)	Bacterial cell membrane (polymyxins) and bacterial cell wall/penicillin-binding proteins (meropenem)
Adapalene/Benzoyl Peroxide Gel 0.3-2.5%	Adapalene/Benzoyl Peroxide Gel 0.3-2.5%	Derm Research, PLLC	marketed	Retinoid + peroxide combination	Retinoic acid receptors (adapalene); bacterial cell membrane and proteins (benzoyl peroxide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibiotic class)

1. Bausch Health Americas, Inc. · 2 drugs in this class
2. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
3. BioVersys AG · 1 drug in this class
4. Bosnalijek D.D · 1 drug in this class
5. Capital Medical University · 1 drug in this class
6. Dr. Reddy's Laboratories Limited · 1 drug in this class
7. Incheon St.Mary's Hospital · 1 drug in this class
8. Jomaa Pharma GmbH · 1 drug in this class
9. King Abdulaziz University · 1 drug in this class
10. Menzies School of Health Research · 1 drug in this class